This selection bias is associated with sparingly clinical attempts at immunotherapy in EGFR-mutant ASC patients, as EGFR-mutant NSCLC is generally considered to be less responsive to immunotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.